CTMX financials
CytomX Therapeutics (CTMX) financials: revenue, profit and margins by year and quarter, the balance sheet and cash flow.
- CTMX revenue was $76.20M in fiscal 2025, net income -$20.37M.
CTMX income statement, yearly
| Year | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 | $76.20M | – | -$22.36M | -$20.37M | – |
| 2024 | $138.10M | – | $25.00M | $31.87M | – |
| 2023 | $101.21M | – | -$6.48M | -$569.00K | – |
| 2022 | $53.16M | – | -$101.33M | -$99.32M | – |
| 2021 | $37.31M | – | -$116.04M | -$115.87M | – |
| 2020 | $68.43M | – | -$80.54M | -$64.82M | – |